{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:10085"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:10085","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Which factors predict early discontinuation of antifibrotics in idiopathic pulmonary fibrosis?","abstract":"Introduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early discontinuation of antifibrotics using a mixed methodology approach. Methods: I collected data on 170 patients with IPF (2012-16) prescribed pirfenidone (n=139) or nintedanib (n=31). Retrospective data was collected including demographics, social factors, diagnostics, antifibrotic prescribed, treatment duration and side-effects. We undertook focus groups and patient interviews, which were analysed thematically. Results: Commonest side-effects were nausea/vomiting (50%) and appetite loss (40%; pirfenidone) and diarrhoea (79%) and weight loss (25%; nintedanib). DLCO ≤40% (OR=2.46) increased risk of early discontinuation at 30-days, with males (OR=0.41) and skin side-effects (OR=0.09) associated with reduced risk. At 90-days, deconditioning side effects (OR=2.58) increased risk of early discontinuation, whereas males (OR=0.39) and gastrointestinal side effects (OR=0.40) reduced risk. Thematic analysis suggested side-effects were tolerable and social factors were not considered barriers by patients. Conclusion: Female gender and DLCO ≤40% were predictors of early discontinuation, compared with social factors. Low DLCO has been shown to predict increased mortality therefore progressive disease would increase risk of early discontinuation.","abstract_html":"Introduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early discontinuation of antifibrotics using a mixed methodology approach. Methods: I collected data on 170 patients with IPF (2012-16) prescribed pirfenidone (n=139) or nintedanib (n=31). Retrospective data was collected including demographics, social factors, diagnostics, antifibrotic prescribed, treatment duration and side-effects. We undertook focus groups and patient interviews, which were analysed thematically. Results: Commonest side-effects were nausea/vomiting (50%) and appetite loss (40%; pirfenidone) and diarrhoea (79%) and weight loss (25%; nintedanib). DLCO ≤40% (OR=2.46) increased risk of early discontinuation at 30-days, with males (OR=0.41) and skin side-effects (OR=0.09) associated with reduced risk. At 90-days, deconditioning side effects (OR=2.58) increased risk of early discontinuation, whereas males (OR=0.39) and gastrointestinal side effects (OR=0.40) reduced risk. Thematic analysis suggested side-effects were tolerable and social factors were not considered barriers by patients. Conclusion: Female gender and DLCO ≤40% were predictors of early discontinuation, compared with social factors. Low DLCO has been shown to predict increased mortality therefore progressive disease would increase risk of early discontinuation.","abstract_has_math":false,"creators":["Bhomra, Parminder Singh"],"institution":"University of Birmingham","degree_name":"m_sc","degree_level":"m_sc","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-07","date_published":"2020-07","updated_at":"2026-11-19T09:31:02Z","subjects":["RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/10085/7/Bhomra2020MScByRes_Redacted.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A10085","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Bhomra, Parminder Singh"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2020-07-20"]},{"key":"dc:date.issued","label":"Date","values":["2020-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Applied Health Research"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/10085/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["m_sc"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["m_sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/10085/7/Bhomra2020MScByRes_Redacted.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Introduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early discontinuation of antifibrotics using a mixed methodology approach. Methods: I collected data on 170 patients with IPF (2012-16) prescribed pirfenidone (n=139) or nintedanib (n=31). Retrospective data was collected including demographics, social factors, diagnostics, antifibrotic prescribed, treatment duration and side-effects. We undertook focus groups and patient interviews, which were analysed thematically. Results: Commonest side-effects were nausea/vomiting (50%) and appetite loss (40%; pirfenidone) and diarrhoea (79%) and weight loss (25%; nintedanib). DLCO ≤40% (OR=2.46) increased risk of early discontinuation at 30-days, with males (OR=0.41) and skin side-effects (OR=0.09) associated with reduced risk. At 90-days, deconditioning side effects (OR=2.58) increased risk of early discontinuation, whereas males (OR=0.39) and gastrointestinal side effects (OR=0.40) reduced risk. Thematic analysis suggested side-effects were tolerable and social factors were not considered barriers by patients. Conclusion: Female gender and DLCO ≤40% were predictors of early discontinuation, compared with social factors. Low DLCO has been shown to predict increased mortality therefore progressive disease would increase risk of early discontinuation."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Which factors predict early discontinuation of antifibrotics in idiopathic pulmonary fibrosis?"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Bhomra, Parminder Singh"],"dc:date":["2020-07-20"],"dc:date.issued":["2020-07"],"dc:description.abstract":["Introduction: Pirfenidone and nintedanib are recommended in idiopathic pulmonary fibrosis (IPF). Randomised controlled trials have shown discontinuation rates of 14-33%; clinical audit in our regional centre showed a rate of 18.4%. I aimed to establish the main factors, which predict early discontinuation of antifibrotics using a mixed methodology approach. Methods: I collected data on 170 patients with IPF (2012-16) prescribed pirfenidone (n=139) or nintedanib (n=31). Retrospective data was collected including demographics, social factors, diagnostics, antifibrotic prescribed, treatment duration and side-effects. We undertook focus groups and patient interviews, which were analysed thematically. Results: Commonest side-effects were nausea/vomiting (50%) and appetite loss (40%; pirfenidone) and diarrhoea (79%) and weight loss (25%; nintedanib). DLCO ≤40% (OR=2.46) increased risk of early discontinuation at 30-days, with males (OR=0.41) and skin side-effects (OR=0.09) associated with reduced risk. At 90-days, deconditioning side effects (OR=2.58) increased risk of early discontinuation, whereas males (OR=0.39) and gastrointestinal side effects (OR=0.40) reduced risk. Thematic analysis suggested side-effects were tolerable and social factors were not considered barriers by patients. Conclusion: Female gender and DLCO ≤40% were predictors of early discontinuation, compared with social factors. Low DLCO has been shown to predict increased mortality therefore progressive disease would increase risk of early discontinuation."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/10085/7/Bhomra2020MScByRes_Redacted.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Applied Health Research"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/10085/"],"dc:subject":["RC Internal medicine"],"dcterms:accessrights":["public"],"dc:title":["Which factors predict early discontinuation of antifibrotics in idiopathic pulmonary fibrosis?"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["m_sc"],"dc:type.qualificationname":["m_sc"]},"updated_at":"2026-11-19T09:31:02Z"}